The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Tanashyan M.M.

Research Center of Neurology

Raskurazhev A.A.

Scientific Center of Neurology

Kornilova A.A.

Scientific Center of Neurology

Cerebrovascular diseases and personalized prevention

Authors:

Tanashyan M.M., Raskurazhev A.A., Kornilova A.A.

More about the authors

Journal: Russian Journal of Preventive Medicine. 2021;24(2): 76‑81

DOI: 10.17116/profmed20212402176

Views: 3280

Downloaded: 182

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Tanashyan MM, Raskurazhev AA, Kornilova AA. Cerebrovascular diseases and personalized prevention. Russian Journal of Preventive Medicine. 2021;24(2):76‑81. (In Russ.)
https://doi.org/10.17116/profmed20212402176

 
МСФ на ЯМ
Close metadata
Recommended articles:
Possibilities of coro­nary artery calcification asse­ssment for cardiovascular risk stra­tification. Russian Journal of Preventive Medi­cine. 2024;(9):117-122
The improvement of the specialized medi­cal care for patients with peri­pheral arte­rial athe­rosclerosis in the Yaro­slavl region. Russian Journal of Preventive Medi­cine. 2024;(12):16-23
Treatment of patients with ishe­mic stroke in the vertebral-basilar system in acute period: expe­rience of using the neuroprotective drug Mexi­dol. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(2):78-84
Lipo­protein(a) and triglyceride-rich lipo­proteins — asso­ciation with recu­rrent nonfatal myocardial infa­rction in patients with early mani­festation of coro­nary artery disease. Russian Cardiology Bulletin. 2024;(1):29-37
CT-predictors of unfa­vorable outcome in hemo­rrhagic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3-2):37-41
Enda­rterectomy from supe­rficial femo­ral artery in patients with type 2 diabetes mellitus. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(3):285-293
Influence of gene­tic poly­morphism of the chemokine rece­ptor CCR5 on clinical course of coro­nary artery disease and resu­lts of percutaneous coro­nary inte­rventions. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(4):401-409
The value of reva­scularisation of athe­rosclerotic lesions of the inno­minate artery at the asymptomatic stage of the disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8-2):72-82
Fore­nsic characteristic of sudden death cases in subjects with meta­bolic syndrome. Fore­nsic Medi­cal Expe­rtise. 2024;(4):54-57
Giant popliteal artery aneurysm. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(1):115-119

The mortality rate of the population of the Russian Federation due to cerebrovascular diseases was more than 260 thousand people in 2018. Personalized medicine is potentially capable of improving the management of risk factors for cardiovascular diseases. At the same time, insufficient attention is often paid to the gender characteristics of patients, although women have a higher increase in cardiovascular events with age compared to men. Atherosclerosis and atherosclerotic plaque destabilization are among the most common causes of ischemic thrombotic events. Antiplatelet therapy is the main method of preventing cerebral thrombotic complications; however, the prescription of these drugs in the context of primary prevention is associated with a number of unresolved issues. The article is a literature review highlighting the importance of controlling personified CVD risk factors based on a multidisciplinary approach.

Keywords:

personalized prevention
cerebrovascular disease
atherosclerosis
acetylsalicylic acid

Authors:

Tanashyan M.M.

Research Center of Neurology

Raskurazhev A.A.

Scientific Center of Neurology

Kornilova A.A.

Scientific Center of Neurology

Received:

20.02.2020

Accepted:

09.10.2020

List of references:

  1. Federal’naya sluzhba gosudarstvennoj statistiki. Smertnost’ naseleniya po prichinam smerti v 2018 godu. M.: Rosstat; 2019. Accessed January 4, 2021. (In Russ.). https://www.gks.ru/free_doc/2018/demo/t3_3.xls
  2. Piradov MA, Maksimova MYu, Tanashyan MM. Insul’t: poshagovaya instrukciya. M.: GEOTAR-Media; 2019. (In Russ.).
  3. Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, Bennett DA, Moran AE, Sacco RL, Anderson L, Truelsen T, O’Donnell M, Venketasubramanian N, Barker-Collo S, Lawes CM, Wang W, Shinohara Y, Witt E, Ezzati M, Naghavi M, Murray C. Global and regional burden of stroke during 1990—2010: findings from the Global Burden of Disease Study 2010. Lancet. 2014;383(9913):245-254.  https://doi.org/10.1016/s0140-6736(13)61953-4
  4. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai S, de Simone G, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Greenlund KJ, Hailpern SM, Heit JA, Ho PM, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, McDermott MM, Meigs JB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Rosamond WD, Sorlie PD, Stafford RS, Turan TN, Turner MB, Wong ND, Wylie-Rosett J. Heart disease and stroke statistics — 2011 update: a report from the American Heart Association. Circulation. 2011;123(4):18-209.  https://doi.org/10.1161/CIR.0b013e3182009701
  5. Schleidgen S, Klingler C, Bertram T, Rogowski WH, Marckmann G. What is personalized medicine: sharpening a vague term based on a systematic literature review. BMC Med Ethics. 2013;14:55.  https://doi.org/10.1186/1472-6939-14-55
  6. Markus HS. Stroke genetics: prospects for personalized medicine. BMC Med. 2012;10:113.  https://doi.org/10.1186/1741-7015-10-113
  7. O’Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, Rangarajan S, Islam S, Pais P, McQueen MJ, Mondo C, Damasceno A, Lopez-Jaramillo P, Hankey GJ, Dans AL, Yusoff K, Truelsen T, Diener HC, Sacco RL, Ryglewicz D, Czlonkowska A, Weimar C, Wang X, Yusuf S. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010;376(9735):112-123.  https://doi.org/10.1016/S0140-6736(10)60834-3
  8. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, Fang MC, Fisher M, Furie KL, Heck DV, Johnston SC, Kasner SE, Kittner SJ, Mitchell PH, Rich MW, Richardson D, Schwamm LH, Wilson JA; on behalf of the American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45:2160-2236. https://doi.org/10.1161/STR.0000000000000024
  9. Kim J, Thrift AG, Nelson MR, Bladin CF, Cadilhac DA. Personalized medicine and stroke prevention: where are we? Vasc Health Risk Manag. 2015;11:601-611.  https://doi.org/10.2147/VHRM.S77571
  10. Zuern CS, Lindemann S, Gawaz M. Platelet function and response to aspirin: gender-specific features and implications for female thrombotic risk and management. Semin Thromb Hemost. 2009;35(3):295-306.  https://doi.org/10.1055/s-0029-1222608
  11. Maksimova MYu, Sazonova VYu, Airapetova AS. Gendernye osobennosti narushenii mozgovogo krovoobrashcheniya v razlichnykh vozrastnykh gruppakh. Annaly klinicheskoi i ehksperimental’noi nevrologii. 2019;13(3):11-19. (In Russ.).
  12. Smith EE, Saposnik G, Biessels GJ, Doubal FN, Fornage M, Gorelick PB, Seshadri S. Prevention of Stroke in Patients With Silent Cerebrovascular Disease: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2016;48(2):44-71.  https://doi.org/10.1161/STR.0000000000000116
  13. Filis K, Toufektzian L, Galyfos G, Sigala F, Kourkoveli P, Georgopoulos S, Vavuranakis M, Vrachatis D, Zografos G. Assessment of the vulnerable carotid atherosclerotic plaque using contrastenhanced ultrasonography. Vascular. 2017;25(3):316-325.  https://doi.org/10.1177/1708538116665734
  14. Gulevskaya TS, Morgunov VA, Anufriev PL. Struktura ateroskleroticheskih blyashek karotidnogo sinusa i narusheniya mozgovogo krovoobrashcheniya. Annals of Clinical and Experimental Neurology. 2010;4(1):13-19. Accessed January 4, 2021. (In Russ.). https://cyberleninka.ru/article/n/struktura-ateroskleroticheskih-blyashek-karotidnogo-sinusa-i-narusheniya-mozgovogo-krovoobrascheniya
  15. Evdokimenko AN, Chechetkin AO, Druina LD, Tanashyan MM. Otsenka neovaskulyarizatsii ateroskleroticheskoi blyashki karotidnogo sinusa s pomoshch’yu kontrast-usilennogo UZI. Vestnik Rossiiskogo gosudarstvennogo meditsinskogo universiteta. 2019;4:25-33. (In Russ.). https://doi.org/10.24075/vrgmu.2019.057
  16. Varetto G, Gibello L, Castagno C, Quaglino S, Ripepi M, Benintende E, Gattuso A, Garneri P, Zan S, Capaldi G, Bertoldo U, Rispoli P. Use of Contrast Enhanced Ultrasound in Carotid Atherosclerotic Disease: Limits and Perspectives. Biomed Res Int. 2015;2015:293163. https://doi.org/10.1155/2015/293163
  17. Tanashyan MM, Raskurazhev AA, Shabalina AA, Lagoda OV, Gnedovskaya EV. Biomarkery tserebral’nogo ateroskleroza: vozmozhnosti rannei diagnostiki I prognozirovaniya individual’nogo riska. Annaly klinicheskoi i ehksperimental’noi nevrologii. 2015;9(3):20-25. Accessed January 4, 2021. (In Russ.).
  18. Tanashyan MM, Ionova VG, Orlov SV, Omel’chenko NG, Shabalina AA, Kostyreva MV. Hronicheskie cerebrovaskulyarnye zabolevaniya, metabolicheskij sindrom i sostoyanie sistem gemoreologii i gemostaza. Terapevticheskij arhiv. 2010;82(10):19-24. (In Russ.).
  19. Liu L, Gao YH, Cao J, Zhang HX, Fan L, Hu GL, Hu YX, Li XL, Zou X, Li JH. High prevalence of aspirin resistance in elderly patients with cardiovascular disease and metabolic syndrome. J Geriatr Cardiol. 2016;13(6):531-536.  https://doi.org/10.11909/j.issn.1671-5411.2016.06.009
  20. Grandl G, Wolfrum C. Hemostasis, endothelial stress, inflammation, and the metabolic syndrome. Semin Immunopathol. 2018;40(2):215-224.  https://doi.org/10.1007/s00281-017-0666-5
  21. Piradov MA, Illarioshkin SN, Tanashyan MM. Nevrologiya XXI veka: diagnosticheskie, lechebnye i issledovatel’skie tekhnologii. Rukovodstvo dlya vrachej. V 3 tomah. M.: OOO ATMO; 2015. (In Russ.).
  22. Gordon T, Kannel WB, Hjortland MC, McNamara PM. Menopause and coronary heart disease. The Framingham Study. Ann Intern Med. 1978;89:157-161.  https://doi.org/10.7326/0003-4819-89-2-157
  23. Rosenberg L, Hennekens CH, Rosner B, Belanger C, Rothman KJ, Speizer FE. Early menopause and the risk of myocardial infarction. Am J Obstet Gynecol. 1981;139:47-51.  https://doi.org/10.1016/0002-9378(81)90410-5
  24. Maksimova MYu, Chechetkin AO, Moskvicheva AS, Shabalina AA. Aterotromboticheskii insul’t u zhenshchin: trombogennyi potentsial krovi i sosudistaya stenka. Annaly klinicheskoi i ehksperimental’noi nevrologii. 2020;14(1):25-32. (In Russ.).
  25. Meyer DM, Eastwood JA, Compton MP, Gylys K, Zivin JA, Ovbiagele B. Sex differences in antiplatelet response in ischemic stroke. Womens Health (Lond). 2011;7(4):465-474.  https://doi.org/10.2217/WHE.11.45
  26. Bellemain-Appaix A. Traitement antiagrégant plaquettaire chez la femme: une spécificité liée au sexe? Annales de Cardiologie et d’Angéiologie. 2016;65(6):395-403.  https://doi.org/10.1016/j.ancard.2016.10.008
  27. Johnston SC, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Wong KSL. Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack. New England Journal of Medicine. 2016;375(1):35-43.  https://doi.org/10.1056/NEJMoa1603060
  28. Schwartz KA. Aspirin resistance: a clinical review focused on the most common cause, noncompliance. The Neurohospitalist. 2011;1(2):94-103.  https://doi.org/10.1177/1941875210395776
  29. Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomized trials. Lancet. 2009;373:1849-1860. https://doi.org/10.1016/S0140-6736(09)60503-1
  30. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, Franklin BA, Goldstein LB, Greenland P, Grundy SM, Hong Y, Miller NH, Lauer RM, Ockene IS, Sacco RL, Sallis JF Jr, Smith SC Jr, Stone NJ, Taubert KA. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation. 2002;106:388-391.  https://doi.org/10.1161/01.CIR.0000020190.45892.75
  31. Bibbins-Domingo K. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2016;164:836-845.  https://doi.org/10.7326/M16-0577
  32. Meschia JF, Bushnell C, Boden-Albala B, Braun LT, Bravata DM, Chaturvedi S, Creager MA, Eckel RH, Elkind MS, Fornage M, Goldstein LB, Greenberg SM, Horvath SE, Iadecola C, Jauch EC, Moore WS, Wilson JA; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Functional Genomics and Translational Biology; Council on Hypertension. Guidelines for the Primary Prevention of Stroke A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2014;45:3754-3832. https://doi.org/10.1161/STR.0000000000000046
  33. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Munoz D, Smith SC Jr, Virani SS, Williams KA Sr, Yeboah J, Ziaeian B. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140:596-646.  https://doi.org/10.1161/CIR.0000000000000678
  34. Whitlock EP, Burda BU, Williams SB, Guirguis-Blake JM, Evans CV. Bleeding risks with aspirin use for primary prevention in adults: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2016;164(12):826-835.  https://doi.org/10.7326/M15-2112
  35. Smith EE, Markus HS. New Treatment Approaches to Modify the Course of Cerebral Small Vessel Diseases. Stroke. 2020;51(1):38-46.  https://doi.org/10.1161/STROKEAHA.119.024150
  36. Dawson J, Broomfield N, Dani K, Dickie DA, Doney A, Forbes K, Houston G, Kean S, Lees K, McConnachie A, Muir KW, Quinn T, Struthers A, Walters M. Xanthine Oxidase Inhibition for the Improvement of Long-Term Outcomes Following Ischaemic Stroke and Transient Ischaemic Attack (XILO-FIST) — protocol for a randomised double blind placebo-controlled clinical trial. Eur Stroke J. 2018;3:281-290.  https://doi.org/10.1177/2396987318771426
  37. Lee SJ, Lee JS, Choi MH, Lee SE, Shin DH, Hong JM. Cilostazol improves endothelial function in acute cerebral ischemia patients: a double-blind placebo controlled trial with flow-mediated dilation technique. BMC Neurol. 2017;17:169.  https://doi.org/10.1186/s12883-017-0950-y
  38. Xiong Z, Lu W, Zhu L, Zeng L, Shi C, Jing Z, Xiang Y, Li W, Tsang CK, Ruan Y, Huang L. Dl-3-n-Butylphthalide treatment enhances hemodynamics and ameliorates memory deficits in rats with chronic cerebral hypoperfusion. Front Aging Neurosci. 2017;9:238.  https://doi.org/10.3389/fnagi.2017.00238
  39. Pauls MM, Moynihan B, Barrick TR, Kruuse C, Madigan JB, Hainsworth AH, Isaacs JD. The effect of phosphodiesterase-5 inhibitors on cerebral blood flow in humans: a systematic review. J Cereb Blood Flow Metab. 2018;38:189-203.  https://doi.org/10.1177/0271678X17747177
  40. Richman IB, Owens DK. Aspirin for Primary Prevention. Medical Clinics of North America. 2017;101(4):713-724.  https://doi.org/10.1016/j.mcna.2017.03.004
  41. Caprio FZ, Sorond FA. Cerebrovascular Disease: Primary and Secondary Stroke Prevention. Med Clin North Am. 2019;103(2):295-308.  https://doi.org/10.1016/j.mcna.2018.10.001
  42. Astronaut Cardiovascular Health and Risk Modification (Astro-CHARM). 10-Year ASCVD Risk Calculator with Coronary Artery Calcium. Accessed September 21, 2018. https://astrocharm.org/calculator-working

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.